Premium
Glycine transporter inhibitor promising for cognition in schizophrenia patients
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30738
Subject(s) - schizophrenia (object oriented programming) , transporter , placebo , cognition , glycine , medicine , pharmacology , psychiatry , psychology , chemistry , biochemistry , amino acid , alternative medicine , pathology , gene
Patients with schizophrenia who were randomized to the novel glycine transporter inhibitor BI 425809 saw significant improvement in cognition compared with placebo in a 12‐week Phase 2 study. The most promising results were reported for daily doses of 10 and 25 mg. Study results were published in the March 2021 issue of Lancet Psychiatry .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom